Skip to main content
SBFM
NASDAQ Life Sciences

Sunshine Biopharma's Q2 Loss Deepens as ATM Sales Add $1.7M and Warrant Overhang Expands

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.16
Mkt Cap
$2.854M
52W Low
$1.1
52W High
$24.3
52W Position info
5.5% above low
Off High info
95% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SBFM is trading near its 52-week low of $1.1 (5.5% above the low) on light trading volume (0.1× avg).

Summary

Q2 loss narrows slightly but gross margin falls sharply; ATM sales and warrant adjustments add significant dilution risk.


Key Events · Earnings and Guidance · SBFM

  • Q2 Net Loss of $1.56M

    Revenue fell 1.6% to $9.26M while gross margin dropped to 26.2% from 36.4%, driving a net loss of $1.56M ($1.15 per share).

  • ATM Sales Raise $1.72M

    From July 27 to August 12, 2026, the company sold 1,430,521 shares under its $4M ATM program for $1,722,555 in net proceeds.

  • Series B Warrant Overhang Expands

    ATM sales triggered an adjustment to 25,477,133 Series B warrants at $1.2202 per share, versus 3.88M shares outstanding.

  • Director Compensation in Stock

    On August 7, 2026, the company issued 58,300 shares to a director for services, adding to dilution.


Analysis · SBFM · Life Sciences

The Q2 2026 10-Q reveals a net loss of $1.56 million on revenue of $9.26 million, with gross margin compressed to 26.2% from 36.4% a year earlier. A $5.1 million public offering in May was followed by sales of 1.43 million shares under the $4 million ATM, generating $1.72 million in net proceeds. Those ATM sales triggered a Series B warrant adjustment to 25.5 million warrants at $1.22, creating a massive overhang relative to the 3.88 million shares outstanding. Management estimates a cash runway of 27 months, but the warrant structure and continued losses suggest further dilution is likely.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SBFM was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $1.10 to $24.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SBFM - Latest Insights

SBFM
Nov 12, 2026, 11:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $2.70 info
Change: $0 (0%) info
Market Cap: $2.055M info
SBFM
Nov 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.70 info
Change: -$0.110 (-4%) info
Market Cap: $2.055M info
SBFM
Nov 12, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.70 info
Change: -$0.100 (-4%) info
Market Cap: $2.055M info
SBFM
Oct 22, 2026, 9:25 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.1638
Real-time Price: $2.70 info
Change: Reverse Stock Split info
Market Cap: $2.055M info
SBFM
Oct 14, 2026, 5:21 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.232
Real-time Price: $2.70 info
Change: Reverse Stock Split info
Market Cap: $2.055M info